Literature DB >> 7557143

The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes.

M Tinel1, M A Robin, J Doostzadeh, M Maratrat, F Ballet, N Fardel, J el Kahwaji, P Beaune, M Daujat, G Labbe.   

Abstract

BACKGROUND & AIMS: Interleukin (IL) 2 is used in advanced cancers, but its effects on cytochrome P450 remain unknown. Other cytokines down-regulate hepatic cytochrome P450, but it is not known whether this involves cytokine receptors. The aim of this study was to determine whether the IL-2 receptor is expressed on hepatocytes and whether its activation by IL-2 depresses cytochrome P450 in cultured rat hepatocytes.
METHODS: A monoclonal antibody specific for the rat IL-2 receptor alpha chain was used to label the receptor, whereas effects on cytochrome P450 were determined after 24 hours of culture with human recombinant IL-2 (5000 U/mL).
RESULTS: The presence of the IL-2 receptor in hepatocytes was shown by immunoblots, flow cytometry, and scanning confocal microscopy. IL-2 caused a 46% decrease in total cytochrome P450; a 35%, 35%, 36%, 26%, and 56% decrease in immunoreactive cytochrome P4501A1, 2B, 2C11, 2D1, and 3A, respectively; and a marked decrease in cytochrome P4503A2 and 2C11 messenger RNAs. Addition to the culture medium of the anti-receptor antibody or the tyrosine kinase inhibitor genistein prevented the IL-2-mediated decrease in cytochrome P450.
CONCLUSIONS: IL-2 down-regulates the expression of cytochrome P450 genes in cultured rat hepatocytes by interacting with its receptor expressed on hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557143     DOI: 10.1016/0016-5085(95)90648-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Increased oxidative DNA damage and hepatocyte overexpression of specific cytochrome P450 isoforms in hepatitis of mice infected with Helicobacter hepaticus.

Authors:  M A Sipowicz; P Chomarat; B A Diwan; M A Anver; Y C Awasthi; J M Ward; J M Rice; K S Kasprzak; C P Wild; L M Anderson
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Authors:  Jane R Kenny; Maggie M Liu; Andrew T Chow; Justin C Earp; Raymond Evers; J Greg Slatter; Diane D Wang; Lei Zhang; Honghui Zhou
Journal:  AAPS J       Date:  2013-06-21       Impact factor: 4.009

Review 4.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

5.  Use of duplex PCR-CTPP methods for CYP2E1RsaI/IL-2 T-330G and IL-1B C-31T/TNF-A T-1031C polymorphisms.

Authors:  Yoshiko Atsuta; Haruya Kawase; Nobuyuki Hamajima; Kazuko Nishio; Yoshimitsu Niwa; Daisuke Tanaka; Kazuhito Yamamoto; Akiko Tamakoshi
Journal:  Mol Diagn       Date:  2005

6.  Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.

Authors:  M A Robin; M Maratrat; M Le Roy; F P Le Breton; E Bonierbale; P Dansette; F Ballet; D Mansuy; D Pessayre
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

7.  Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.

Authors:  P N Morcos; S A Moreira; B J Brennan; S Blotner; N S Shulman; P F Smith
Journal:  Eur J Clin Pharmacol       Date:  2013-06-14       Impact factor: 2.953

8.  Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium.

Authors:  Madhusudana R Chaluvadi; Ryan D Kinloch; Beatrice A Nyagode; Terrilyn A Richardson; Malik J Raynor; Melanie Sherman; Leposava Antonovic; Henry W Strobel; Dirck L Dillehay; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

Review 9.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

10.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.